Table Of Content

T HE ORGANIC CHEMISTRY OF D R UG SYNTHESIS VOLUME 4 DANIEL LEDNICER National Cancer Institute Bethesda, Maryland LESTER A. MITSCHER Department of Medicinal Chemistry The University of Kansas Lawrence, Kansas with GUNDA I. GEORG Department of Medicinal Chemistry The University of Kansas Lawrence, Kansas A Wiley-Interscience Publication John Wiley & Sons, Inc. New York / Chichester / Brisbane / Toronto / Singapore Copyright © 1990 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: (Revised for volume 4) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-Interscience publication." Includes bibliographical references and Index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic-Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs-Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-85548-0(v. 4) Printed in the United States of America 10 987654321 We dedicate this book to Beryle and Betty who continue to support us in every imaginable way and to the memory of Katrina Mitscher-Chapman (1958-1987) who was looking forward with her customary enthusiasm to helping us prepare the manuscript. I cannot tell how the truth may be; I say the tale as 'twas said to me. Sir Walter Scott, "The Lay of the Last Minstrel" Preface Over a decade and a half have flown by since we started on the preparation of the first volume in this series. We did not at that time envisage a series at all but simply a book which filled what we then perceived as a vacuum. There were not in print in the midnineteen seventies any contempo- rary monographs in the English language dedicated to the synthesis of medicinal agents. The result was the original Organic Chemistry of Drug Synthesis. The reception accorded that volume con- firmed that there was indeed a place for a book devoted to that subject matter. Having laid the groundwork, it seemed worthwhile to rectify a number of omissions present in the book and at the same time to bring the coverage for compounds included in the compilation to a common date. The result was of course Volume 2 and the birth of a series. The next volume, 3, was produced at the time we again felt the need to update our narrative; a semidecenial period was settled upon since it seemed to represent the best compromise between currency and a sufficient body of material to merit treatment in a monograph. The volume at hand continues the series; it covers the chemistry of those compounds which have been granted a United States Adopted Name (USAN) in the five years between 1983 and 1987. The bulk of the references thus fall in the 1980s; the reader will note occasional much older references. We suppose that those represent compounds which were synthesized many years ago and set on the shelf at that time; they were then revived for clinical development for one reason or another and a USAN applied for. It is well known that regulatory approval of new chemical entities has slowed markedly over the past decade. Some would even argue that the very rate of decrease is accelerating. This phenomenon has been attributed to a wide variety of causes, none of which are particularly ger- mane to this volume. It is thus surprising, and pleasing, to note that the decreased probability of bringing a given new chemical entity to market has not led to a diminution in the rate of acquisition of new generic names as noted in USAN and USP Dictionary of Drug Names. The 300 odd compounds discussed in this volume are within a few entities of the number covered in the preced- ing volume. The acquisition of 60 new generic names each year has been so uniform over the past decade that this should perhaps be recognized as a new physical constant! This relatively steady rate of addition of new generic names has resulted in books which are quite uniform in size, at least after accounting for the text which was used to bring the subject up to date . The individual chapter titles do not show a corresponding uniformity; the composition of x PREFACE the more recent volumes in some ways represents a socio economic history of research in medicinal chemistry. The first volume in this series, for example, contained a sizable chapter devoted to compounds based on the phenothiazine nucleus. This had disappeared by the second volume due to a dearth of new material. This in all probability simply represents a shift away from the research which took place on these compounds in the midnineteen fifties. Occasional chapters have lasted through all four volumes. One of these, to the authors' surprise is that devoted to " Steroids." That particular chapter is, however, by now a mere shadow of those which appeared in the first two volumes. Some chapters have persisted but changed significant- ly in content. "Alicyclic Compounds" has evolved from a collection of miscellany to a virtual compendium of prostaglandin syntheses. The diligent reader will note that succeeding volumes increasingly show agents which are the result of rational drug design of the synthesis targets. The older rationale for preparing specific compounds—to produce a hopefully superior and clearly patentable modification of a successful new drug—still however persists. Note that the present volume lists seven quinolone antibacterial agents, the same number of dihydropyridine calcium channel blockers, and no fewer than an even dozen angiotensin-converting enzyme inhibitors. Once the initial lead is discovered, a very significant expenditure of effort takes place; this persists until it becomes clear that no further improve- ments are taking place and that new entries are unlikely to gain a share of the market, This book is addressed primarily to practitioners in the field who seek a quick overview of the synthetic routes which have been used to access specific classes of therapeutic agents. Publica- tions of syntheses of such compounds in the open literature remains a sometimes thing. One can, however, be certain that any compound which has commercial potential will be covered by a patent application. Many of the references are thus to the patent literature. Graduate students in medicinal and organic chemistry may find this book useful as an adjunct to the more traditional texts in that it provides many examples of actual applications of the chemistry which is the subject of their study. This volume, like those which came before, presumes a good working knowledge of chemical synthesis and at least nodding acquaintance with biology and pharmacology. Finally, the authors express their gratitude to Ms. Vicki Welch who patiently and skillful- ly prepared the many versions of this book including the final camera ready copy. Rockville, Maryland DANIEL LEDNICER Lawrence, Kansas LESTER A. MITSCHER Lawrence, Kansas GUNDA I. GEORG January, 1990 Contents Chapter 1. Aliphatic and Alicyclic Compounds 1 1, Acyclic Compounds 1 2. Alicyclic Compounds 4 3. Prostaglandins 8 4. Organoplatinum Complexes 15 References 17 Chapter 2. Monocyclic Aromatic Compounds 19 1. Phenylpropanolamines 19 2. Phenoxypropanolamines 25 3. Alkylbenzenes and Alkoxybenzenes 29 4. Derivatives of Aniline 35 5. Benzoic Acid Derivatives 39 6. Diphenylmethanes 46 7. Miscellaneous Compounds 49 References 52 Chapter 3. Polycyclic Aromatic Compounds and Thier Reduction Products 55 L Naphthalenes and Tetralins 55 2. Indanes and Indenes 58 3. Fluorenes 62 4. Anthraquinones 62 5. Reduced Anthracenes 63 References 64 Chapter 4. Steroids 65 1. Estranes 65 2. Androstanes 68 3. Pregnanes 70 References 77 Chapter 5. Five-Membered Ring Heterocycles 79 1. One Heteroatom 79 2. Two Heteroatoms 85 3. Three Heteroatoms 98 References 98